Related Experiment Videos

Expression of HSV-TK suicide gene in primary T lymphocytes: the dog as a preclinical model

E M Weissinger1, M Franz, C Voss

  • 1MHH, Hematology/Oncology, Hannover, Germany. weissinger.eva@mh-hannover.de

Insights

Gene therapy using suicide genes like herpes simplex virus thymidine kinase (HSV-TK) in T cells offers a way to control graft-versus-host disease. This study optimized canine T cell gene transfer, showing its preclinical feasibility.

Area of Science:

  • * Immunology
  • * Gene Therapy
  • * Oncology

Background:

  • * Adoptive immunotherapy aims to regulate graft-versus-host disease using suicide gene-modified T cells.
  • * Herpes simplex virus thymidine kinase (HSV-TK) is a suicide gene utilized for T cell regulation.

Purpose of the Study:

  • * To optimize retroviral infection of canine T cells for gene therapy applications.
  • * To evaluate the efficacy of gene-modified T cells in a preclinical canine model.

Main Methods:

  • * Canine T cells were stimulated with phytohemagglutinin (PHA) or interleukin-2.
  • * Cells were co-cultivated with irradiated virus-producing cells (PG13 packaging cell line).
  • * Transduction efficiency was assessed, and transduced cells were enriched via immunoselection.

Main Results:

  • * Transduction efficiencies ranged from 4% to 45% using the PG13 packaging cell line.
  • * Immunoselection achieved up to 98% purity of transduced cells.
  • * Transfused cells converted mixed chimerism to 100% and transferred antigen-specific immunity, detected via PCR for HSV-TK.

Conclusions:

  • * Retroviral gene transfer into canine T cells was successfully optimized.
  • * Gene-modified T cells demonstrated therapeutic potential in a preclinical setting.
  • * The canine model is feasible for studying gene therapy strategies for graft-versus-host disease.

Related Concept Videos